Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Disease Awareness Ads, Not Ban On DTC, Is Best Marketing Path – Morris

Executive Summary

A ban on direct-to-consumer advertising may have the unintended consequence of shifting marketing dollars into less transparent promotional vehicles, consultant Louis Morris said during a Pharmaceutical Marketing Partnerships Institute meeting in Philadelphia July 25

You may also be interested in...



FDA Ad Division Letter Surge Shows Focus On Prominence Of Risk Information

An upcoming FDA draft guidance on fair balance in promotional materials could benefit manufacturers following a spate of warning letters from the agency's ad division citing the prominence of risk information

PhRMA To Unveil DTC Guidelines In August; Board Gives Preliminary Approval

The Pharmaceutical Research & Manufacturers of America expects to have voluntary guidelines for direct-to-consumer advertising in place by August

Bristol’s DTC Moratorium Will Affect Muraglitazar, Abatacept Launches

Muraglitazar and abatacept are likely to be the first Bristol-Myers Squibb products significantly affected by the company's recent moratorium on direct-to-consumer advertising during a drug's first 12 months on the market

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS046140

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel